SCHEMBL337129

SCHEMBL337129

CCCCc1ccc([Mg]Br)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.48
CA1 P00915 1/20 0.48
ALDH1A1 P00352 3/20 0.47
HSD17B10 Q99714 2/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
SKP2 Q13309 1/20 0.46
ESR1 P03372 2/20 0.45
ADRA2A P08913 2/20 0.45
ADORA3 P0DMS8 2/20 0.45
TACR2 P21452 2/20 0.45
SLC6A2 P23975 2/20 0.45
SLC6A4 P31645 2/20 0.45
SLC6A3 Q01959 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
SHBG P04278 1/20 0.45
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.45
HSPD1 P10809 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9720081 0.94 ESR1 (0.53) CA2ALDH1A1HSD17B10ESR1ADRA2A
SCHEMBL4882552 0.92 PTGS2 (0.57) ALDH1A1HSD17B10ESR1ADRA2AADORA3
SCHEMBL15302863 0.92 PTGS2 (0.57) ALDH1A1HSD17B10ESR1ADRA2AADORA3
SCHEMBL10426156 0.92 PTGS2 (0.57) ALDH1A1HSD17B10ESR1ADRA2AADORA3
SCHEMBL18281616 0.92 PTGS2 (0.57) ALDH1A1HSD17B10ESR1ADRA2AADORA3
SCHEMBL2561141 0.92 PTGS2 (0.57) ALDH1A1HSD17B10ESR1ADRA2AADORA3
SCHEMBL10482087 0.88 RARB (0.53) ALDH1A1HSD17B10HPGDSMN1; SMN2ESR1
SCHEMBL10528133 0.87 HSD17B10 (0.56) ALDH1A1HSD17B10HPGDSMN1; SMN2ESR1
SCHEMBL3044257 0.86 LPL (0.45) CA2ALDH1A1KDM4EPLK1LPL
SCHEMBL10571328 0.86 MAOB (0.39) ALDH1A1HSD17B10ESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637475-B2 Method for producing naphthylsilole, naphthylsilole containing heterocyclic group, and graphene nanoribbon containing heterocyclic group NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) 2026-05-26 US disclosed
EP-4116308-B1 METHOD FOR PRODUCING NAPHTYLSILOLE, NAPHTHYLSILOLE CONTAINING HETEROCYCLIC GROUP, AND GRAPHENE NANORIBBON CONTAINING HETEROCYCLIC GROUP NATIONAL UNIV CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) 2026-05-13 EP disclosed
US-20230121865-A1 METHOD FOR PRODUCING NAPHTHYLSILOLE, NAPHTHYLSILOLE CONTAINING HETEROCYCLIC GROUP, AND GRAPHENE NANORIBBON CONTAINING HETEROCYCLIC GROUP NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) 2023-04-20 US disclosed
EP-4116308-A1 NAPHTHYL SILOLE PRODUCTION METHOD, NAPHTHYL SILOLE HAVING HETEROCYCLIC GROUP, AND GRAPHENE NANORIBBONS HAVING HETEROCYCLIC GROUP National University Corporation Tokai National Higher Education and Research System (JP) 2023-01-11 EP disclosed
EP-3940013-A1 GRAPHENE NANORIBBON AND METHOD FOR PRODUCING SAME Taoka Chemical Co., Ltd. (JP) 2022-01-19 EP disclosed
CN-113677731-A Graphene nanoribbons and methods of making the same 田冈化学工业株式会社 2021-11-19 CN disclosed
WO-2020184625-A1 GRAPHENE NANORIBBON AND METHOD FOR PRODUCING SAME 国立大学法人東海国立大学機構 2020-09-17 WO disclosed
EP-2234973-B1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INT BV (NL) 2014-07-02 EP disclosed
US-8569495-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2013-10-29 US disclosed
US-8097644-B2 Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist ALLERGAN, INC. (US) 2012-01-17 US disclosed
EP-1856010-A1 METHODS FOR OLIGOMERIZING OLEFINS Exxonmobil Chemical Patents Inc. (US) 2007-11-21 EP disclosed
US-20070232682-A1 Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist ALLERGAN, INC. (US) 2007-10-04 US disclosed
EP-1618094-B1 SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INST FOR PHARM DISCOVERY INC (US) 2007-09-05 EP disclosed
US-20060247399-A1 Methods for oligomerizing olefins EXXONMOBIL CHEMICAL PATENTS INC. 2006-11-02 US disclosed
WO-2006099053-A1 METHODS FOR OLIGOMERIZING OLEFINS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2006-09-21 WO disclosed
EP-1618094-A1 SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES The Institutes for Pharmaceutical Discovery, LLC (US) 2006-01-25 EP disclosed
US-20050009817-A1 Substituted heteroaryls INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. 2005-01-13 US disclosed
WO-2004099159-A1 SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) 2004-11-18 WO disclosed
US-6096894-A Production method of 2-(p-alkylphenyl)pyridine compound SUMIKA FINE CHEMICALS CO., LTD. (JP) 2000-08-01 US disclosed
EP-0976736-A1 Production method of 2-(p-alkylphenyl)pyridine compound SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232682-A1 Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist S1PR1, S1PR2, S1PR3 CA2 2068/4885CA1 4744/4885ALDH1A1 2262/4885
US-20050009817-A1 Substituted heteroaryls PTPRS, PTPRO, PTPRR CA2 4281/4885CA1 4632/4885ALDH1A1 477/4885
US-20230121865-A1 METHOD FOR PRODUCING NAPHTHYLSILOLE, NAPHTHYLSILOLE CONTAINING HETEROCYCLIC GROUP, AND GRAPHENE NANORIBBON CONTAINING HETEROCYCLIC GROUP C1R, INSR, CCKBR CA2 3255/4885CA1 2660/4885ALDH1A1 2786/4885
US-12637475-B2 Method for producing naphthylsilole, naphthylsilole containing heterocyclic group, and graphene nanoribbon containing heterocyclic group LBR, INSR, IGF1R CA2 2449/4885CA1 1947/4885ALDH1A1 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.